<?xml version="1.0" encoding="UTF-8"?>
<p>In outbreaks of emerging infectious diseases for which no proven efficacious vaccines exist but investigational vaccines have been developed, it is important both to rapidly test the investigational vaccines and, if effective, to deploy them. Following the 2014â€“2016 Ebola epidemic, the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations, and other bodies committed to developing investigational vaccines for emerging infectious diseases [
 <xref rid="pmed.1002632.ref001" ref-type="bibr">1</xref>,
 <xref rid="pmed.1002632.ref002" ref-type="bibr">2</xref>]. They aim to evaluate them for immunogenicity and safety, so that promising candidates will be available for efficacy testing and possible deployment when an epidemic occurs.
</p>
